313 related articles for article (PubMed ID: 22265115)
21. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
[TBL] [Abstract][Full Text] [Related]
22. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.
Schwarz T; Spaczynski M; Kaufmann A; Wysocki J; Gałaj A; Schulze K; Suryakiran P; Thomas F; Descamps D
BJOG; 2015 Jan; 122(1):107-18. PubMed ID: 25208608
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.
Kim YJ; Kim KT; Kim JH; Cha SD; Kim JW; Bae DS; Nam JH; Ahn WS; Choi HS; Ng T; Bi D; OK JJ; Descamps D; Bock HL
J Korean Med Sci; 2010 Aug; 25(8):1197-204. PubMed ID: 20676333
[TBL] [Abstract][Full Text] [Related]
25. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Schulze K; Poncelet SM; Catteau G; Thomas F; Descamps D
Hum Vaccin; 2011 Sep; 7(9):958-65. PubMed ID: 21892005
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
28. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
Schwarz TF; Galaj A; Spaczynski M; Wysocki J; Kaufmann AM; Poncelet S; Suryakiran PV; Folschweiller N; Thomas F; Lin L; Struyf F
Cancer Med; 2017 Nov; 6(11):2723-2731. PubMed ID: 28984053
[TBL] [Abstract][Full Text] [Related]
29. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
30. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
De Carvalho N; Teixeira J; Roteli-Martins CM; Naud P; De Borba P; Zahaf T; Sanchez N; Schuind A
Vaccine; 2010 Aug; 28(38):6247-55. PubMed ID: 20643092
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Wheeler CM; Skinner SR; Del Rosario-Raymundo MR; Garland SM; Chatterjee A; Lazcano-Ponce E; Salmerón J; McNeil S; Stapleton JT; Bouchard C; Martens MG; Money DM; Quek SC; Romanowski B; Vallejos CS; Ter Harmsel B; Prilepskaya V; Fong KL; Kitchener H; Minkina G; Lim YKT; Stoney T; Chakhtoura N; Cruickshank ME; Savicheva A; da Silva DP; Ferguson M; Molijn AC; Quint WGV; Hardt K; Descamps D; Suryakiran PV; Karkada N; Geeraerts B; Dubin G; Struyf F;
Lancet Infect Dis; 2016 Oct; 16(10):1154-1168. PubMed ID: 27373900
[TBL] [Abstract][Full Text] [Related]
32. Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study.
Hu Y; Zhang X; He Y; Ma Z; Xie Y; Lu X; Xu Y; Zhang Y; Jiang Y; Xiao H; Struyf F; Folschweiller N; Jiang J; Poncelet S; Karkada N; Jastorff A; Borys D
Asia Pac J Clin Oncol; 2020 Dec; 16(6):392-399. PubMed ID: 32780946
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
Zhu FC; Li CG; Pan HX; Zhang YJ; Bi D; Tang HW; Datta S
Chin J Cancer; 2011 Aug; 30(8):559-64. PubMed ID: 21801604
[TBL] [Abstract][Full Text] [Related]
36. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Romanowski B; Schwarz TF; Ferguson LM; Ferguson M; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Behre U; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2014; 10(5):1155-65. PubMed ID: 24576907
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
[TBL] [Abstract][Full Text] [Related]
39. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.
Moscicki AB; Wheeler CM; Romanowski B; Hedrick J; Gall S; Ferris D; Poncelet S; Zahaf T; Moris P; Geeraerts B; Descamps D; Schuind A
Vaccine; 2012 Dec; 31(1):234-41. PubMed ID: 23063422
[TBL] [Abstract][Full Text] [Related]
40. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
